On a day when the Nifty 50 index fell by 0.47%, shares of Laurus Labs (₹1,237.90) and Sai Life Sciences (₹1,124) surged by 3%, marking new highs on the National Stock Exchange (NSE). Over the past month, Laurus Labs has seen a 14% increase in share price, while Sai Life's shares have risen by 15%, outpacing the benchmark index's 8.9% rise. Laurus Labs reported a revenue of ₹1,812 crore for Q4FY26, a 5% increase year-on-year, with a profit after tax of ₹281.9 crore. The company's CDMO business has grown significantly, now contributing over 30% of total revenue, up from 13% six years ago. Analysts from Choice Institutional Equities have given Laurus a target price of ₹1,255, while Motilal Oswal maintains a Buy rating with a target price of ₹1,370. Meanwhile, Sai Life Sciences has seen a CAGR of 25% in revenues from FY2022 to FY2025, with a 43% increase in the first nine months of FY2026, supported by strong performance in both discovery and CDMO segments. Despite facing revenue concentration risks due to its reliance on regulated markets, ICRA notes that Sai Life's robust infrastructure and established client relationships may help mitigate competitive pressures.